India's pharmaceutical market is on a trajectory for significant growth, with projections indicating a potential increase to between USD 120 billion and USD 130 billion by 2030, up from an estimated USD 55 billion in 2025.
This anticipated surge is largely attributed to advancements in biologics and the integration of artificial intelligence within the industry. As the sector evolves, pharmaceutical exports, which reached USD 30 billion in 2024-25, are also expected to see remarkable growth, potentially hitting USD 75-80 billion by the end of the decade.
The implications of this growth are substantial, not only for India's economy but also for global healthcare. The rise in biologics and AI-driven solutions could enhance drug development processes and improve patient outcomes, positioning India as a key player in the global pharmaceutical landscape.
As the market expands, stakeholders in the life sciences sector should prepare for shifts in both domestic and international dynamics, fostering innovation and collaboration to capitalize on these emerging opportunities.